Atrial fibrillation (AF), the most frequent cardiac arrhythmia, is associated with increased
morbidity and mortality. 1 Currently available pharmacologic interventions for AF have major
limitations, including limited efficacy and risk of life-threatening ventricular proarrhythmic
side effects. 2–4 Amiodarone, a classical K+ channel blocker that affects also a wide range
of other ion channels and receptors, is currently the most frequently prescribed
antiarrhythmic compound for AF therapy, suggesting that blocking of K+ channels may be a …